On Friday, Corbus Pharmaceuticals earned an upgrade to its Relative Strength (RS) Rating, from 89 to 93.
IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks often have an 80 or better RS Rating as they launch their largest climbs.
Here Are 3 Keys For Successful Stock Investing
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to establish and enter a buying range in heavy trade.
Corbus Pharmaceuticals posted 0% earnings growth in its most recent report, while sales growth came in at -100%.
The company holds the No. 233 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
